4D Molecular Therapeutics (FDMT) Asset Utilization Ratio (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Asset Utilization Ratio data on file, last reported at 0.16 in Q1 2026.

• On a quarterly basis, Asset Utilization Ratio rose 382316.02% year-over-year to 0.16 in Q1 2026; TTM through Mar 2026 was 0.16, a 382316.02% increase from a year earlier, with the FY2025 full-year figure at 0.15, up 183849.42% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.16, down from 0.17 in the prior quarter.
• Over the last five years, Asset Utilization Ratio for FDMT reached as high as 0.17 in Q4 2025 and fell as low as 0.0 in Q3 2024.
• Historically, Asset Utilization Ratio has averaged 0.04 across 5 years, with a median of 0.01 in 2022.
• Across the five-year window, Asset Utilization Ratio sank 99.95% in 2024 and jumped 382316.02% in 2026, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.01 in 2022, then soared by 411.85% to 0.06 in 2023, then plunged by 99.89% to 0.0 in 2024, then surged by 270576.98% to 0.17 in 2025, then decreased by 4.97% to 0.16 in 2026.
• Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.16 in Q1 2026, 0.17 in Q4 2025, and 0.0 in Q3 2025.